Given the potential of LUCAT1 as a therapeutic target in reversing chemoresistance [6], further studies are also needed to investigate if knockdown of LUCAT1 is a viable strategy to treat chemoresistance BC, which is critical for improving the prognosis of late-stage BC patients. The gene discussed is LUCAT1; the disease is breast cancer.